Follica

Follica is a biotechnology company focused on developing innovative hair restoration solutions using a regenerative platform that integrates dermatological science and medicine. Follica, Inc. is a biotechnology firm that specializes in hair regeneration solutions. Founded in 2005 and headquartered in Boston, US, the company has pursued innovative methods to stimulate hair follicles, particularly for androgenetic alopecia in men and women.

The firm has undergone four funding rounds, with the most recent being a Series B raise of USD 0. 11 mn in September 2010 from investors including InterWest Partners, Polaris Partners, and PureTech Ventures. The current company valuation stands at USD 29. 53 mn.

The CEO of Follica is Jason Bhardwaj. Follica, Inc. offers a range of products aimed at addressing hair loss through its unique regenerative platform. The company's treatments are designed to activate dormant hair follicles and promote hair regrowth, targeting conditions like androgenetic alopecia in both men and women.

Follica serves customers primarily in North America and Europe, catering to individual consumers seeking hair loss solutions as well as healthcare providers incorporating advanced treatments into their offerings. Follica generates revenue through a combination of direct-to-consumer sales and B2B partnerships with healthcare professionals. The firm's clients access scientifically validated proprietary treatments for hair restoration, which can be offered as subscription services for ongoing regimens or as one-time product purchases. Their flagship treatments utilize the company's advanced regenerative platform, with pricing reflective of the technology's efficacy.

Sales channels include direct clinic sales and potential online platforms aimed at end users. Looking ahead, Follica plans to expand its product lineup with new treatments designed for broader hair restoration applications. The company is also targeting international market expansion, particularly in Europe and Asia, by the end of 2023. The recent Series B funding of USD 0.

11 mn will support these initiatives, allowing Follica to accelerate product development and enhance its market presence.